Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 3, 2011, Pages 721-731

  Khatri, Amit ^a   Gaber, M Waleed ^b   Brundage, Richard C ^a   Naimark, Michael D ^c   Hanna, Suzan K ^c   Stewart, Clinton F ^c   Kirstein, Mark N ^a,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cerebrospinal fluid; Irinotecan; Pharmacokinetics; Radiation

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DRUG METABOLITE; IRINOTECAN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; BOOTSTRAPPING; CEREBROSPINAL FLUID EXAMINATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RAT; SHAM PROCEDURE; SINGLE DRUG DOSE; SKULL IRRADIATION; STATISTICAL ANALYSIS;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOTRANSFORMATION; BODY WEIGHT; BRAIN; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, RADIATION; HALF-LIFE; MALE; MODELS, STATISTICAL; NONLINEAR DYNAMICS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 80054687830     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1542-3     Document Type: Article

References (38)

1. R Cecchelli V Berezowski S Lundquist M Culot M Renftel MP Dehouck L Fenart 2007 Modelling of the blood-brain barrier in drug discovery and development Nat Rev Drug Discov 6 8 650 661 17667956 10.1038/nrd2368 1:CAS:528:DC%2BD2sXotl2qtLc%3D
2. JF Pizzolato LB Saltz 2003 Irinotecan (Campto) in the treatment of pancreatic cancer Expert Rev Anticancer Ther 3 5 587 593 14599083 10.1586/14737140.3.5.587 1:CAS:528:DC%2BD3sXpt1arsLY%3D
3. S Kudoh Y Fujiwara Y Takada H Yamamoto A Kinoshita Y Ariyoshi K Furuse M Fukuoka 1998 Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group J Clin Oncol 16 3 1068 1074 9508192 1:CAS:528:DyaK1cXitVKitrs%3D
4. CF Verschraegen T Levy AP Kudelka E Llerena K Ende RS Freedman CL Edwards M Hord M Steger AL Kaplan D Kieback A Fishman JJ Kavanagh 1997 Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix J Clin Oncol 15 2 625 631 9053486 1:CAS:528:DyaK2sXhsVams78%3D
5. R Ohno K Okada T Masaoka A Kuramoto T Arima Y Yoshida H Ariyoshi M Ichimaru Y Sakai M Oguro, et al. 1990 An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma J Clin Oncol 8 11 1907 1912 2230878 1:STN:280:DyaK3M%2FjvVWrsA%3D%3D
6. T Satoh M Hosokawa R Atsumi W Suzuki H Hakusui E Nagai 1994 Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino] carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase Biol Pharm Bull 17 5 662 664 7920428 10.1248/bpb.17.662 1:STN:280:DyaK2M%2FgsVansg%3D%3D
7. LP Rivory J Robert 1995 Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan Cancer Chemother Pharmacol 36 2 176 179 7767955 10.1007/BF00689205 1:STN:280:DyaK2M3osFGjtg%3D%3D
8. MC Haaz L Rivory C Riche L Vernillet J Robert 1998 Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions Cancer Res 58 3 468 472 9458091 1:STN:280:DyaK1c7hslaqtw%3D%3D
9. LP Rivory JF Riou MC Haaz S Sable M Vuilhorgne A Commercon SM Pond J Robert 1996 Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients Cancer Res 56 16 3689 3694 8706009 1:CAS:528:DyaK28XltVKksrc%3D
10. HS Friedman WP Petros AH Friedman LJ Schaaf T Kerby J Lawyer M Parry PJ Houghton S Lovell K Rasheed T Cloughsey ES Stewart OM Colvin JM Provenzale RE McLendon DD Bigner I Cokgor M Haglund J Rich D Ashley J Malczyn GL Elfring LL Miller 1999 Irinotecan therapy in adults with recurrent or progressive malignant glioma J Clin Oncol 17 5 1516 1525 10334539 1:CAS:528:DyaK1MXjsF2ms7o%3D
11. HS Friedman MD Prados PY Wen T Mikkelsen D Schiff LE Abrey WK Yung N Paleologos MK Nicholas R Jensen J Vredenburgh J Huang M Zheng T Cloughesy 2009 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 28 4733 4740 19720927 10.1200/JCO.2008.19.8721 1:CAS:528:DC%2BD1MXhtlGgtbbM
12. CM Wilson MW Gaber OM Sabek JA Zawaski TE Merchant 2009 Radiation-induced astrogliosis and blood-brain barrier damage can be abrogated using anti-TNF treatment Int J Radiat Oncol Biol Phys 74 3 934 941 19480972 10.1016/j.ijrobp.2009.02.035 1:CAS:528:DC%2BD1MXmsFyhsr4%3D
13. TJ FitzGerald J Aronowitz M Giulia Cicchetti G Fisher S Kadish YC Lo C Mayo S McCauley J Meyer R Pieters A Sherman 2006 The effect of radiation therapy on normal tissue function Hematol Oncol Clin North Am 20 1 141 163 16580561 10.1016/j.hoc.2006.01.005 1:STN:280:DC%2BD287otlCltQ%3D%3D
14. H Yuan MW Gaber T McColgan MD Naimark MF Kiani TE Merchant 2003 Radiation-induced permeability, leukocyte adhesion in the rat blood-brain barrier: modulation with anti-ICAM-1 antibodies Brain Res 969 1-2 59 69 12676365 10.1016/S0006-8993(03)02278-9 1:CAS:528:DC%2BD3sXisV2msL4%3D
15. Spector R (2010) Nature and consequences of mammalian brain and CSF efflux transporters: four decades of progress. J Neurochem 112(1):13-23
16. JF Deeken W Loscher 2007 The blood-brain barrier, cancer: transporters, treatment, and Trojan horses Clin Cancer Res 13 6 1663 1674 17363519 10.1158/1078-0432.CCR-06-2854 1:CAS:528:DC%2BD2sXivV2gtrg%3D
17. WL Furman CF Stewart CA Poquette CB Pratt VM Santana WC Zamboni LC Bowman MK Ma FA Hoffer WH Meyer AS Pappo AW Walter PJ Houghton 1999 Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children J Clin Oncol 17 6 1815 1824 10561220 1:CAS:528:DyaK1MXktV2qtbw%3D
18. F Bouzom C Laveille H Merdjan R Jochemsen 2000 Use of nonlinear mixed effect modeling for the meta-analysis of preclinical pharmacokinetic data: application to S 20342 in the rat J Pharm Sci 89 5 603 613 10756326 10.1002/(SICI)1520-6017(200005)89:5<603::AID-JPS6>3.0.CO;2-E 1:CAS:528:DC%2BD3cXjtlOitrg%3D
19. MP van den Berg SG Romeijn JC Verhoef FW Merkus 2002 Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity J Neurosci Methods 116 1 99 107 12007987 10.1016/S0165-0270(02)00033-X
20. EC de Lange M Danhof 2002 Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain Clin Pharmacokinet 41 10 691 703 12162757 10.2165/00003088-200241100-00001
21. CE Johanson JA Duncan EG Stopa A Baird 2005 Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route Pharm Res 22 7 1011 1037 16028003 10.1007/s11095-005-6039-0 1:CAS:528:DC%2BD2MXmt1ynur0%3D
22. ZB Redzic MB Segal 2004 The structure of the choroid plexus and the physiology of the choroid plexus epithelium Adv Drug Deliv Rev 56 12 1695 1716 15381330 10.1016/j.addr.2004.07.005 1:CAS:528:DC%2BD2cXnslOiu7s%3D
23. D Qin J Ma J Xiao Z Tang 1997 Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents Am J Clin Oncol 20 3 263 265 9167750 10.1097/00000421-199706000-00011 1:STN:280:DyaK2szhtVGrsQ%3D%3D
24. de la Fouchardiere C, Negrier S, Labrosse H, Martel Lafay I, Desseigne F, Meeus P, Tavan D, Petit-Laurent F, Rivoire M, Perol D, Carrie C (2010) Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 77(2):409-413
25. Rich TA, Kirichenko AV (2001) Camptothecin schedule and timing of administration with irradiation. Oncology (Williston Park) 15(3 Suppl 5):37-41
26. RH Mathijssen S Marsh MO Karlsson R Xie SD Baker J Verweij A Sparreboom HL McLeod 2003 Irinotecan pathway genotype analysis to predict pharmacokinetics Clin Cancer Res 9 9 3246 3253 12960109 1:CAS:528:DC%2BD3sXotFCksL8%3D
27. FR Luo PV Paranjpe A Guo E Rubin P Sinko 2002 Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1 Drug Metab Dispos 30 7 763 770 12065434 10.1124/dmd.30.7.763 1:CAS:528:DC%2BD38XltVGrurk%3D
28. JY Han HS Lim ES Shin YK Yoo YH Park JE Lee HT Kim JS Lee 2008 Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer Lung Cancer 59 1 69 75 17766002 10.1016/j.lungcan. 2007.07.019
29. Q Zhou A Sparreboom EH Tan YB Cheung A Lee D Poon EJ Lee B Chowbay 2005 Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer Br J Clin Pharmacol 59 4 415 424 15801936 10.1111/j.1365-2125.2004.02330. x 1:CAS:528:DC%2BD2MXktFals7w%3D
30. BL Urquhart RB Kim 2009 Blood-brain barrier transporters and response to CNS-active drugs Eur J Clin Pharmacol 65 11 1063 1070 19727692 10.1007/s00228-009-0714-8 1:CAS:528:DC%2BD1MXhtlSltbjE
31. T Imai 2006 Human carboxylesterase isozymes: catalytic properties and rational drug design Drug Metab Pharmacokinet 21 3 173 185 16858120 10.2133/dmpk.21.173 1:CAS:528:DC%2BD28Xpt1Siu74%3D
32. M Mori M Hosokawa Y Ogasawara E Tsukada K Chiba 1999 cDNA cloning, characterization and stable expression of novel human brain carboxylesterase FEBS Lett 458 1 17 22 10518925 10.1016/S0014-5793(99)01111-4 1:CAS:528:DyaK1MXmsFWitrg%3D
33. R Xie RH Mathijssen A Sparreboom J Verweij MO Karlsson 2002 Clinical pharmacokinetics of irinotecan, its metabolites: a population analysis J Clin Oncol 20 15 3293 3301 12149304 10.1200/JCO.2002.11.073 1:CAS:528: DC%2BD38XmsF2rs7w%3D
34. Z Hu X Yang PC Ho E Chan SY Chan C Xu X Li YZ Zhu W Duan X Chen M Huang H Yang S Zhou 2005 St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats Pharm Res 22 6 902 914 15948034 10.1007/s11095-005-4585-0 1:CAS:528:DC%2BD2MXltVKnur0%3D
35. CF Stewart WC Zamboni WR Crom PJ Houghton 1997 Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice Cancer Chemother Pharmacol 40 3 259 265 9219511 10.1007/s002800050656 1:CAS:528:DyaK2sXjvF2kurY%3D
36. WC Zamboni PJ Houghton J Thompson PJ Cheshire SK Hanna LB Richmond X Lou CF Stewart 1998 Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts Clin Cancer Res 4 2 455 462 9516936 1:CAS:528:DyaK1cXhtlSmtro%3D
37. AP Venook C Enders Klein G Fleming D Hollis CG Leichman R Hohl J Byrd D Budman M Villalona J Marshall GL Rosner J Ramirez H Kastrissios MJ Ratain 2003 A phase I, pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863 Ann Oncol 14 12 1783 1790 14630685 10.1093/annonc/mdg493 1:STN:280:DC%2BD3srltVWnsw%3D%3D
38. Yang XX, Hu ZP, Chan SY, Duan W, Ho PC, Boelsterli UA, Ng KY, Chan E, Bian JS, Chen YZ, Huang M, Zhou SF (2006) Pharmacokinetic mechanisms for reduced toxicities of irinotecan by co-administered thalidomide. Curr Drug Metab 7(4):431-455